|View printer-friendly version|
|Multiple Myeloma Research Foundation (MMRF) Names Millennium Collaborator of the Year|
CAMBRIDGE, Mass., January 23, 2013 – Millennium: The Takeda Oncology Company today announced that the Multiple Myeloma Research Foundation (MMRF) has named Millennium as the first recipient of the MMRF Collaborator Award. The award recognizes Millennium for its outstanding commitment to collaboration to advance the research and development of more effective treatments for multiple myeloma.
“It’s a terrific honor for Millennium to receive the first-ever Collaborator Award from the MMRF,” said Deborah Dunsire, M.D., President and Chief Executive Officer of Millennium. “We are very proud to be partners with the MMRF and extend our gratitude for this award and for the MMRF’s commitment to patients with multiple myeloma.”
“Millennium has demonstrated extraordinary vision and a dedication to transforming multiple myeloma research and drug development to improve outcomes for patients,” said Kathy Giusti, Founder and CEO of the MMRF and a multiple myeloma patient. “In particular, Millennium’s early and enthusiastic support of the MMRF CoMMpass study ensured that this landmark study lost no momentum in opening.”
Additional awards announced by the MMRF included Washington University in St. Louis, which received the MMRF Innovator Award, and a team of researchers from the Dana-Farber Cancer Institute, who received the MMRF Accelerator Award.
MMRF Collaborator Award
The MMRF Collaborator Award recognizes Millennium: The Takeda Oncology Company for its outstanding commitment to collaboration as a means to advance the research and development of more effective treatments for patients with multiple myeloma. The company has also partnered with the MMRC to launch highly innovative clinical trials through the Multiple Myeloma Research Consortium - four trials in 2012 alone and 22 trials overall.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $200 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four four-star rating for nine consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, visit www.themmrf.org.
Millennium: The Takeda Oncology Company, a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a first-in-class proteasome inhibitor, and has a robust clinical development pipeline of product candidates. Millennium Pharmaceuticals, Inc. was acquired by Takeda Pharmaceutical Company Ltd. in May, 2008. The Company’s research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, www.millennium.com.
Editors’ Note: This press release is also available under the Media section of the Company’s website at: www.millennium.com/InTheNews.aspx.